Sold as Capital Soleil 15, Anthelios Sx. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 2 applications for Avobenzone; Ecamsule; Octocrylene (sold as Capital Soleil 15, Anthelios Sx), first approved Jul 21, 2006, with 0 new uses approved and 0 published complete response letters.
| Jul 21, 2006 | Anthelios SxNDA 21502 · New molecular entity, new combination | Loreal USA | 7 | Marketed |
| Oct 2, 2006 | Capital Soleil 15NDA 21501 · New formulation or manufacturer | Loreal USA | 3 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA